# Safety and Efficacy of Cariprazine in Patients With Schizophrenia

> **NCT01104766** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 617 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Cariprazine
- **DRUG:** Aripiprazole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01104766
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-23
- **Primary completion:** 2011-12-20
- **Final completion:** 2011-12-20
- **Target enrollment:** 617 (ACTUAL)
- **Last updated:** 2018-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01104766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01104766, "Safety and Efficacy of Cariprazine in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01104766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*